Browse News
Filter News
Found 183 articles
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
2/28/2023
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2022.
-
After the announcement, Nektar shares dropped 36%, going from $6.47 per share to $4.16.
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results
2/28/2022
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2021.
-
Nektar Therapeutics Reports Third Quarter 2021 Financial Results
11/4/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2021 .
-
Nektar Therapeutics Reports Second Quarter 2021 Financial Results
8/5/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2021.
-
Nektar Therapeutics Reports First Quarter 2021 Financial Results
5/6/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the first quarter ended March 31, 2021.
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
2/25/2021
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2020.
-
Nektar Therapeutics Reports Third Quarter 2020 Financial Results
11/5/2020
Nektar Therapeutics reported financial results for the third quarter ended September 30, 2020.
-
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
8/6/2020
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2020.
-
Nektar Therapeutics Reports First Quarter 2020 Financial Results
5/7/2020
Cash and investments in marketable securities at March 31, 2020 were approximately $1.5 billion as compared to $1.6 billion at December 31, 2019.
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results
2/27/2020
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2019 .
-
In a painful blow to the San Francisco-based company, the committees voted unanimously, 27 to 0, not to recommend approval.
-
Nektar Issues Statement Regarding FDA Advisory Committee Vote for Oxycodegol
1/15/2020
Nektar Therapeutics issued a statement following a meeting of the Food and Drug Administration's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee to discuss the New Drug Application for oxycodegol where the Committees did not recommend approval of oxycodegol.
-
Nektar Therapeutics Reports Financial Results for the Third Quarter of 2019
11/6/2019
Nektar Therapeutics reported its financial results for the third quarter ended September 30, 2019.
-
Nektar Announces Key Executive Promotions
10/1/2019
Nektar Therapeutics announced several promotions on its executive leadership team
-
Wrapping up the month of August, there are technically four PDUFA dates on the calendar, although one was approved two months early and another may be delayed as the U.S. Food and Drug Administration reevaluates its policies regarding opioid pain medications. Here’s a look.
-
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2019
8/8/2019
Company to Host Conference Call with Analysts to Review Financial Results and Provide Update on the NKTR-214 Program
-
Nektar noted that the delay is not due to an issue with its novel opioid formulation, but rather with new policies regarding opioids being implemented at the FDA.
-
Inheris Biopharma was formed as Nektar awaits the FDA approval of a pain medication that does not have the euphoric side effects of other opioids.
-
Nektar Announces the Launch of Inheris Biopharma, Inc.
5/23/2019
Nektar Therapeutics announced the formation of Inheris Biopharma, Inc., a wholly-owned subsidiary of Nektar and a CNS-focused company.